BACKGROUND: Urinary tract cytology (UTC) specimens diagnosed using high-risk indeterminate categories such as "atypical urothelial cells, cannot exclude high-grade urothelial carcinoma" (AUC-H) or "suspicious for high-grade urothelial carcinoma" (SHGUC) have a high rate of detection of high-grade urothelial carcinoma on subsequent biopsy. Although urologists are familiar with such terminology, it is unclear whether patients receive appropriate follow-up when UTC is ordered by nonurologists. In the current study, the authors investigated whether the use of AUC-H versus SHGUC altered patient management among nonurologists. METHODS: Specimens signed out as AUC-H or SHGUC were identified from the archives of the study institution, which included periods of time before the use of the standardized Johns Hopkins Hospital template, during use of the Johns Hopkins Hospital template, and after institution of The Paris System for Reporting Urinary Cytology. RESULTS: Approximately one-half of the specimens diagnosed as AUC-H were not investigated further when ordered by nonurologists. Patients with specimens diagnosed as AUC-H received fewer subsequent biopsies (14% vs 53%; P <.001) when the specimens were ordered by nonurologists versus urologists, despite having similar rates of high-grade urothelial carcinoma on follow-up biopsy (67% vs 66%). When specimens ordered by nonurologists were diagnosed as SHGUC, these patients received more follow-up (100%) compared with those whose specimens were diagnosed as AUC-H (44%; P <.001). Patients with specimens ordered by nonurologists also received more follow-up biopsies when these were diagnosed as suspicious (60%) compared with patients whose specimens were diagnosed as AUC-H (14%; P <.001). CONCLUSIONS: Use of the word "suspicious" for the high-risk indeterminate category results in greater follow-up among nonurologists ordering UTC specimens. Cancer Cytopathol 2018;126:282-8. V C 2018 American Cancer Society.
INTRODUCTION
Urinary tract cytology (UTC) specimens are obtained in a wide variety of clinical settings. Patients undergoing surveillance for bladder cancer typically have UTC specimens submitted for examination for which a urologist is the ordering physician. 1 Similarly, patients with unexplained hematuria may be referred to a urology office for workup, which typically involves examination of a UTC specimen. 2 Urologists are likely to follow up with UTC specimen diagnoses and be familiar with the nomenclature used by their local laboratory, which may include indeterminate diagnoses such as "atypical" or "suspicious." the emergency room, outpatient office, or nonurologic hospital ward, and these clinicians may be unfamiliar with such terminology and have a decreased opportunity to follow up with their patients. We desired to determine the use of UTC within the study institution by nonurologists, and whether patients were appropriately followed after receiving an indeterminate diagnosis. To do this, we searched for patients with UTC specimens diagnosed using the higher risk indeterminate category ("suspicious for high-grade urothelial carcinoma" [SHGUC] or "atypical urothelial cells, cannot exclude high-grade urothelial carcinoma" [AUC-H]), which have high rates of highgrade urothelial carcinoma (HGUC) on subsequent tissue biopsy.
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MATERIALS AND METHODS
After approval by the Johns Hopkins Medicine institutional review board, the pathology data system at the Johns Hopkins Hospital was searched for UTC specimens that were signed out as AUC-H during a 5-year period from 2008 through 2013, during our use of the standardized Johns Hopkins Hospital template (JHHT) and before establishment of The Paris System for Reporting Urinary Cytology (TPS). 4, [11] [12] [13] We also performed a similar search for cases diagnosed as SHGUC during the same period, within the year after the establishment of TPS at Johns Hopkins Hospital (2016-2017) and during a period before use of the JHHT (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . Representative images of specimens diagnosed as AUC-H and SHGUC are provided (Fig. 1) . During use of the JHHT, standardized cytomorphologic criteria for a diagnosis of AUC-H were not defined. During use of TPS, SHGUC specimens contained cells meeting the qualitative criteria but not quantitative criteria for HGUC or contained cells that did not meet the qualitative criteria for HGUC. A retrospective study within the institutional laboratory indicated that some AUC-H specimens would have upgraded or downgraded diagnoses when TPS criteria were applied. 14 Specimens then were categorized according to the specialty of the location at which the test was ordered. We categorized the specialty groups into urologists and nonurologists. We then evaluated electronic medical records to determine the clinical management of these patients. For specimens obtained between 2008 and 2013, we evaluated clinical follow-up for a 1-year period after specimen procurement. In general, we categorized follow-up based on whether patients were referred to a urologist, had a tissue biopsy taken from the urinary tract within 1 year, or had a subsequent urine specimen submitted within 6 months. Patients who did not receive such follow-up were considered to have not received follow-up specific for their atypical or suspicious diagnosis. In such cases, we determined whether the clinical records indicated that the ordering clinician acknowledged the atypical or suspicious diagnosis or not, despite the patient not receiving follow-up.
Statistical Analysis
Statistical comparisons were performed using the Fisher exact test.
RESULTS
Study Cohorts
A total of 516 UTC specimens were identified in the study institution archives with a diagnosis of AUC-H from 2008 through 2013. Of these, 473 specimens (92%) were ordered by a urologist and 43 (8%) were ordered by a nonurologist (Fig. 2) . A total of 276 UTC specimens were identified as having a diagnosis that included a diagnosis of SHGUC (Fig. 3 ). Of these, 261 specimens were ordered by a urologist and 15 were ordered by a nonurologist.
When Ordered by Nonurologists, Patients With Specimens Diagnosed as AUC-H Were Less Likely to Receive a Follow-Up Biopsy
Of the 473 specimens ordered by a urologist and diagnosed as AUC-H, 73% (344 specimens) were followed with a biopsy within 1 year. Of these, 66% (226 specimens) were found to have HGUC on biopsy. Of the remaining follow-up biopsies, 17% (58 of 344 specimens) were benign and 17% (60 of 344 specimens) found lowgrade urothelial neoplasia, denuded epithelium, dysplasia, or other atypical findings. By comparison, among patients for whom a nonurologist ordered the specimen, only 14% of specimens (6 of 43 specimens) received a follow-up biopsy within 1 year (Table 1 ). Of these, 1 was benign, 4 demonstrated HGUC, and 1 specimen demonstrated lowgrade urothelial neoplasia.
When Ordered by Nonurologists, Patients With Specimens Diagnosed as AUC-H Were Less Likely to Receive Follow-Up Regarding Their Indeterminate Diagnosis
Because a significant number of patients managed by nonurologists did not undergo a biopsy, we examined their clinical records to determine the follow-up received. Of those 37 patients not receiving a biopsy, 11 (30%) were followed with a repeat urine specimen within 6 months. A total of 13 patients (35%) had clinical documentation indicating that the atypical diagnosis would not be evaluated further. Nine patients (24%) continued to have documented visits at our hospital system without evidence of follow-up specific to their atypical UTC. Four patients From 1995 through 2006, 106 UTC specimens were diagnosed as SHGUC; only 3 were ordered by nonurologists. Of these, 1 patient was followed clinically without additional cystoscopy or urine specimens and 2 patients underwent biopsy and were found to have HGUC. Among the 103 UTC specimens ordered by urologists, 82 received a subsequent biopsy, 63 of which had HGUC identified.
During use of the JHHT, 45 specimens were diagnosed as SHGUC, 7 of which were ordered by nonurologists. Five of these patients underwent subsequent biopsy, all of which found HGUC. The sixth patient received a urology consult but did not undergo cystoscopy or further investigation with additional UTC specimens. An additional UTC specimen was provided from the seventh patient, which yielded a benign diagnosis. Among the 38 specimens ordered by urologists, 29 received follow-up biopsy and 21 of these were diagnosed as HGUC.
Because TPS was instituted relatively recently, follow-up intervals were more limited during this period (2016-2017). However, all patients with UTC specimens ordered by nonurologists received follow-up during the study. During this period, 125 specimens were diagnosed as SHGUC, 5 of which were ordered by nonurologists. Two of these patients had subsequent biopsies, 1 with a diagnosis of HGUC and the second with denuded urothelium, a finding associated with carcinoma in situ. Two other patients had subsequent UTC specimens with atypical and suspicious diagnoses, respectively, for which they continued to be followed at the time of last follow-up. A fifth patient received a urology consult but had not yet undergone cystoscopy or submitted an additional UTC specimen at the time of last follow-up. Among specimens ordered by urologists, 86 of 120 patients underwent a follow-up biopsy, 66 of which were diagnosed as HGUC.
Overall, patients with UTC specimens ordered by nonurologists received significantly greater follow-up when the diagnosis was SHGUC compared with AUC-H (100% vs 44%; P < .0001) ( Table 2 ). In addition, these patients had a higher rate of biopsy (60% vs 14%; P < .0005) and a higher rate of HGUC on overall followup (53% vs 9.3%; P < .0001). Among UTC specimens ordered by urologists, the biopsy rate was not significantly greater among patients with specimens diagnosed as SHGUC versus those with specimens diagnosed as AUC-H (75% vs 73%).
DISCUSSION
During our longest period using standardized nomenclature, a diagnosis of AUC-H resulted in significantly different follow-up depending on the ordering physician (urologist vs nonurologist). To a certain extent this should be expected, because the patients of urologists tend to be under constant surveillance and to have a higher pretest probability of HGUC given the propensity of disease recurrence. 16 However, studies at the study institution as well as others have demonstrated a significant risk of HGUC (60%-95%) among patients with this diagnosis who undergo a subsequent biopsy, which argues that all patients with a high-risk diagnosis should receive follow-up to specifically exclude HGUC. [4] [5] [6] [7] That so few patients with a diagnosis of AUC-H received specific follow-up by nonurologists suggests the possibility that such a diagnosis should be treated as a "critical action value" or "critical diagnosis" when the specimen is ordered by a nonurologist. 17, 18 Although hematuria is the most common presenting symptom of bladder cancer, the majority of cases of hematuria are not related to bladder cancer and are secondary to other etiologies (eg, urolithiasis). Because of the low pretest probability associated with hematuria initially examined by a nonurologist, one might assume that indeterminate diagnoses are unlikely to be associated with subsequent HGUC. However, in the current study, 12 such patients had HGUC definitively diagnosed on follow-up, which comprises 40% of the 30 patients who had any follow-up specific to their diagnosis. This indicates that UTC may be a critical part of the initial hematuria workup, assuming that nonurologists can be properly educated regarding UTC diagnoses and/or notified about potentially consequential diagnoses (such as AUC-H or SHGUC). It should be noted that the current American Urological Association guidelines recommend against the use of routine cytology for patients with microscopic hematuria and the referral of patients with macroscopic hematuria to a urologist for a full workup. 19 This recommendation is due to concerns that cytology specimens ordered by nonurologists may not be appropriately followed and that falsepositive test results may cause an unnecessary emotional burden and diagnostic procedures. The low follow-up rates noted among nonurologists in the current study support this stance. TPS contains 2 indeterminate categories, AUC and SHGUC, which, respectively, indicate a lower risk and higher risk of HGUC. Before TPS, the study institution as well as others used different terminology for the higher risk indeterminate category, which included the terminology "cannot exclude HGUC" (AUC-H). We found that all patients with specimens ordered by nonurologists and receiving a diagnosis of SHGUC received specific followup for this diagnosis over 3 periods of time, including one that overlapped with use of the term AUC-H. This suggests that diagnostic nomenclature that contains the word "suspicious" is taken more seriously by ordering nonurologists, whereas "cannot exclude" may be more likely to be ignored. This also supports the use of such nomenclature in TPS, as opposed to wording that may be taken less seriously.
Although the study laboratory received a large number of UTC specimens over this period, the number of specimens with a diagnosis of SHGUC was limited given that it was not part of our standardized nomenclature until TPS was established. Furthermore, the majority of specimens at the study institution are ordered by urologists, Original Article
